UTRECHT, The Netherlands and EDINBURGH, UK, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that it has been awarded a €1.5 million EUREKA Eurostars grant (“iMOD-ReACT”) with Aquila BioMedical, Ltd. to jointly develop novel immunological assays supporting the selection of potent bispecific antibodies that positively modulate tumor immunity with superior potency and...
Oct. 2 (Bloomberg) -- Frank Aquila, a partner at Sullivan & Cromwell LLP, talks with Bloomberg's Lori Rothman about the outlook for mergers and acquisitions....
Nov. 6 (Bloomberg) -- Frank Aquila, a partner at Sullivan & Cromwell LLP, talks with Bloomberg's Lori Rothman about the outlook for mergers and acquisitions....
Jan. 18 (Bloomberg) -- Frank Aquila, partner at Sullivan & Cromwell LLP, talks with Bloomberg Law's Lee Pacchia about the U.S. economy and prospects for ......
Ein Jahr nach dem Beben gleicht die einst sehenwerte Altstadt von L'Aquila noch immer einem Trümmerfeld. Es ist fast nichts passiert, kaum geräumt, nichts ......